![Todd Davis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Todd Davis
Directeur Général chez
LIGAND PHARMACEUTICALS INCORPORATED
Fortune : 51 M $ au 31/05/2026
Profil
Todd Christopher Davis was the founder of Healthcare Royalty Management LLC, founded in 2007, where the title held was Managing Partner from 2007 to 2018.
Mr. Davis was the founder of Royaltyrx Capital LLC, founded in 2018, where the title held was Managing Partner.
Current jobs include Chief Executive Officer & Director at Ligand Pharmaceuticals, Inc. since 2022; Chairman & Chief Executive Officer at Benuvia Therapeutics, Inc.; Chairman & Chief Executive Officer at Next Frontier Holdings, Inc. since 2019; Chairman at Helomics Corp.; Director at Ligand UK Ltd. since 2022; Director at Palvella Therapeutics, Inc. since 2017; Director at Virocell Biologics Ltd.; Independent Director at Palvella Therapeutics, Inc. since 2024; Director at Pelthos Therapeutics, Inc. since 2023.
Former jobs include Chairman at Channel Therapeutics Corp.; Vice Chairman at Suneva Medical, Inc.; Chairman at Chromocell Therapeutics Corp.; Independent Director at BioDelivery Sciences International, Inc. from 2018 to 2022; Director at AcuFocus, Inc.; Director at Verus Pharmaceuticals, Inc.; Managing Director at Cowen Group, Inc. from 2007 to 2009; Director at Artes Medical, Inc. in 2008; Director at Nuron Biotech, Inc.; Independent Director at Vaxart, Inc. from 2019 to 2023; Director at Harvard Business School Health Industry Alumni Association; Principal at Abbott Laboratories from 1990 to 1995; Partner at Apax Partners, Inc. from 2001 to 2006; Principal at Elan Pharmaceuticals LLC from 1997 to 2001; Partner at Paul Capital Partners LP.
Education includes an undergraduate degree from United States Naval Academy conferred in 1983 and an MBA from Harvard Business School conferred in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/04/2026 | 163 820 ( 0,82 % ) | 38 M $ | 31/05/2026 | |
0,78 % | 10/06/2025 | 112 547 ( 0,78 % ) | 13 M $ | 31/05/2026 |
0,08 % | 24/11/2025 | 2 917 ( 0,08 % ) | 77 213 $ | 31/05/2026 |
Postes actifs de Todd Davis
| Sociétés | Poste | Début |
|---|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Directeur Général | 05/12/2022 |
| VERNALIS | Directeur/Membre du Conseil | 05/12/2022 |
Virocell Biologics Ltd.
 Virocell Biologics Ltd. BiotechnologyHealth Technology Manufactures viral vectors and gene therapies clinical devices | Directeur/Membre du Conseil | - |
Benuvia Therapeutics, Inc.
 Benuvia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and therapeutic drugs | Directeur Général | - |
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing new therapeutic agents for diseases suffered by patients that lack any treatment choices | Directeur/Membre du Conseil | 01/11/2017 |
Helomics Corp.
 Helomics Corp. Medical/Nursing ServicesHealth Services Provides cancer care development and treatment consulting services | Président | - |
Next Frontier Holdings, Inc. | Directeur Général | 01/11/2019 |
Anciens postes connus de Todd Davis
| Sociétés | Poste | Fin |
|---|---|---|
| VAXART, INC. | Président | 17/03/2023 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Directeur/Membre du Conseil | 22/03/2022 |
| ░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Todd Davis
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
85
Relations au 1er degré
25
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 25 |
|---|---|
Abbott Laboratories
 Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Apax Partners, Inc.
 Apax Partners, Inc. Investment ManagersFinance Apax Partners focuses exclusively on long-term investments in growth companies. The firm invests globally in the following sectors: (1) financial and business services (2) healthcare (3) media (4) retail and consumer and (5) technology and telecommunications. They target large companies with strong, established market positions and the potential to expand. Apax Partners' investment strategy is to grow businesses by acting as a catalyst for change and to employ clear processes to maximize the value of their portfolio. | Finance |
Ligand UK Ltd.
 Ligand UK Ltd. BiotechnologyHealth Technology Engages in research and development & sells pharmaceutical products | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial stage pharmaceutical company to patients living with chronic pain | Health Technology |
AcuFocus, Inc.
 AcuFocus, Inc. Medical SpecialtiesHealth Technology Manufactures and wholesales ophthalmic medical device | Health Technology |
Verus Pharmaceuticals, Inc.
 Verus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides pediatric-oriented pharmaceutical products | Health Technology |
Elan Pharmaceuticals LLC
 Elan Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Cowen Group, Inc. /Old/
 Cowen Group, Inc. /Old/ Investment Banks/BrokersFinance Provides investment banking services | Finance |
Paul Capital Partners LP
 Paul Capital Partners LP Investment ManagersFinance Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments. The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented. The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing. The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market. The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles. For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship. Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners. They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives. Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization. Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s). Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities. Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments. | Finance |
Artes Medical, Inc.
 Artes Medical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures, commercializes of injectable aesthetic products for dermatology and plastic surgery markets | Health Technology |
United States Naval Academy
 United States Naval Academy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Helomics Corp.
Helomics Corp. Medical/Nursing ServicesHealth Services Provides cancer care development and treatment consulting services | Health Services |
Healthcare Royalty Management LLC
 Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty invests in companies located in the United States. The firm targets companies operating in the field of biopharmaceutical, biotechnology and medical device sectors. It provides financing for buyout transactions in the form of royalty monetization, corporate financing and debt. | Finance |
Suneva Medical, Inc.
 Suneva Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and commercializes novel, differentiated aesthetic products | Electronic Technology |
Harvard Business School Health Industry Alumni Association | |
Nuron Biotech, Inc.
 Nuron Biotech, Inc. BiotechnologyHealth Technology Markets and develops vaccines for the prevention and treatment of infectious diseases | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing new therapeutic agents for diseases suffered by patients that lack any treatment choices | Health Technology |
Vaxart, Inc.
 Vaxart, Inc. BiotechnologyHealth Technology Develops vaccines | Health Technology |
Royaltyrx Capital LLC
 Royaltyrx Capital LLC Financial ConglomeratesFinance Provides investment services in pharmaceutical industries | Finance |
Benuvia Therapeutics, Inc.
Benuvia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and therapeutic drugs | Health Technology |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Manufactures viral vectors and gene therapies clinical devices | Health Technology |
Next Frontier Holdings, Inc. | |
Chromocell Therapeutics Corp.
 Chromocell Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which develops and commercializes new therapeutics to alleviate pain | Health Technology |
